Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 22, 2026, reports a significant regulatory milestone. The US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received prior ROS1 kinase inhibitor therapy. This marks GSK's first approved medicine in the lung cancer space and is a key asset from the recently completed acquisition of Nuvalent, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a current report focused on a regulatory approval event rather than a periodic financial statement.
Material Changes and Clinical Data
The primary material change is the FDA approval of Jideytro, which occurred ahead of the original target action date of September 18, 2026. The approval was based on the ARROS-1 phase I/II clinical trial results:
- Population: 117 patients with ROS1-positive NSCLC previously treated with a ROS1 inhibitor.
- Objective Response Rate (ORR): 44% (95% CI: 34-53%).
- Duration of Response (DOR): 82% at six months and 69% at 12 months.
- Safety Profile: Common adverse reactions (≥15%) included oedema, peripheral neuropathy, constipation, fatigue, and dyspnoea.
The drug is designed to address efficacy and tolerability challenges, including coverage of ROS1 resistance mutations and blood-brain barrier penetration.
Guidance, Outlook, and Management Commentary
Management views this approval as validation of GSK's strategy to acquire assets with validated targets. Tony Wood, Chief Scientific Officer, highlighted the rapid progression from development to approval and the urgent need for effective treatments in this patient population.
Pipeline Outlook:
- Neladalkib (NVL-655): For ALK-altered NSCLC; currently under FDA review with a target decision date of November 27, 2026.
- NVL-330: Investigational treatment for HER2-altered NSCLC.
- Risvutatug rezetecan (Ris-Rez): A B7-H3-targeted antibody-drug conjugate in late-stage development for relapsed small-cell lung cancer, with recently reported positive phase III data.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2025 Form 20-F and Q1 2026 results.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Jideytro in the US market.
- Confirm the status of the FDA review for neladalkib (NVL-655) and the November 2026 decision date.
- Review the integration progress of Nuvalent, Inc. assets into GSK's oncology portfolio.
- Assess the competitive landscape for ROS1-positive NSCLC treatments post-approval.
- Monitor upcoming data readouts for Ris-Rez and other pipeline assets mentioned.